Prednisolone + Voriconazole
Phase 2/3Completed 0 watching 0 views this week๐ Rising
65
Development Stage
โ
Pre-clinicalโ
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Allergic Bronchopulmonary Aspergillosis
Conditions
Allergic Bronchopulmonary Aspergillosis
Trial Timeline
Jun 1, 2013 โ Apr 1, 2016
NCT ID
NCT01621321About Prednisolone + Voriconazole
Prednisolone + Voriconazole is a phase 2/3 stage product being developed by Cipla for Allergic Bronchopulmonary Aspergillosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01621321. Target conditions include Allergic Bronchopulmonary Aspergillosis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01621321 | Phase 2/3 | Completed |
Competing Products
20 competing products in Allergic Bronchopulmonary Aspergillosis
Other Products from Cipla
Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABVApproved
85
Insulin Lispro-aabc + Insulin GlargineApproved
85
CBT124 + EU-sourced Avastinยฎ + Carboplatin + PaclitaxelPhase 3
77
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboPhase 3
77
Budesonide 80 ฮผg and Formoterol Fumarate Dihydrate 4.5 ฮผg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboPhase 3
77